pulmonary hypertension
Conditions
Interventions
We perform MR exam two times of plans before and 3-6 months after therapy.
Sponsors
Graduate School of Medical Science, University of the Ryukyus Department of Radiology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.The patients to perform pharmacotherapy with the vasodilator in for pulmonary hypertension in hospital attached to the University of Ryukyu School of Medicine, Kanagawa circulatory organ respiratory disease center, Sapporo Medical College hospital during a period with December, 2018 from December, 2016. 2.Written informed consent is obtained.
Exclusion criteria
Exclusion criteria: 1.MRI contraindication, relative contraindicated matter pertinence person (claustrophobia, the pregnant woman, the patients implanted metal in the body, the patients with the tattoo) 2.The patients who cannot keep rest 30 minutes or more with a dorsal position 3.Chronic thromboembolic pulmonary hypertension
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change of pulmonary flow measured by PC-MRI in the before and after therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| The change of the measurement values of PC-MRI:Mean velocity, Acceleration time, Peak velocity, maximal change in the flow rate/Acceleration volume, Cardiac index Correlation between pulmonary flow and mean pulmonary arterial pressure and 6 minutes distance walk. | — |
Countries
Japan
Contacts
Public ContactJunji Jyunji
Graduate School of Medical Science, University of the Ryukyus Department of Radiology
Outcome results
None listed